Question 204: Are symptoms of GVHD still present on the date of actual contact (or present at the time of death)?

This question refers to any symptoms of GVHD (acute and / or chronic) observed during the reporting period. This section of the form must be completed if the center reported Yes, acute, or chronic GVHD developed or persisted.

Indicate whether the recipient has active clinical signs / symptoms of acute and/or chronic GVHD on the date of contact (question 1). If the recipient has died, indicate whether GVHD symptoms were present at the time of death.

Question 205: Is the recipient still taking systemic steroids? (Do not report steroids for adrenal insufficiency, ≤ 10 mg/day for adults, < 0.1 mg/kg/day for children)

Indicate whether the recipient is still taking systemic steroids to treat or prevent GVHD on the date of contact. If the recipient is no longer taking systemic steroids for GVHD, report No. If the recipient is still receiving systemic steroids during the reporting period to treat or prevent GVHD, report Yes. Refer to the guidelines included in the question text if the recipient is taking low dose steroids or steroids for adrenal insufficiency.

If the recipient did not receive systemic steroids for acute and / or chronic GVHD during the reporting period, report Not applicable.

Indicate Not applicable in any of the following scenarios:

  • The recipient has never received systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD.
  • This form is being completed for a subsequent HCT and the recipient has never received systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD since the start of the preparative regimen for the most recent infusion (or since the date of the most recent infusion if no preparative regimen is given).
  • The recipient stopped taking systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) to treat or prevent GVHD in a previous reporting period and did not restart systemic steroids (> 10 mg / day for adults or ≥ 0.1 mg / kg / day for children) during the current reporting period.

Indicate Unknown if there is no information to determine if the recipient is still taking systemic steroids. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD on the date of contact.

If the recipient has died prior to the discontinuation of systemic steroids used to treat or prevent acute and / or chronic GVHD, select Yes.

Review the examples below for more information:

Example 1: In the 100-day reporting period, a recipient is on Prednisone at 7 mg per day for the entire reporting period. Is the recipient still taking systemic steroids should be answered as Not applicable since the dose of systemic steroids was never > 10 mg / day.

Example 2: At the beginning of the 6-month reporting period, a recipient is on 20 mg of Prednisone per day. After three months, the dose is decreased to 10 mg per day and is maintained at that level until the end of the reporting period. In this scenario, question 202 should be answered as No since the dose of systemic steroids was ≤ 10 mg / day on the day of contact.

Example 3: Throughout the 100-day reporting period, a recipient is on 30 mg Methylprednisolone given every other day. In this scenario the average daily dose is approximately 15 mg / day. Hence, Is the recipient still taking systemic steroids should be captured as Yes, as the dose of systemic steroids is > 10 mg / day.

Questions 206 – 207: Date final treatment of systemic steroids administered

Indicate whether the date systemic steroids was discontinued is Known or Unknown. If the final treatment date is Known, report the date when the final dose of systemic steroids was administered. For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Question 208: Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?

Indicate whether the recipient is still taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent acute and / or chronic GVHD on the date of contact. If the recipient is still taking non-steroid immunosuppressive agents, report Yes. If the recipient is no longer receiving non-steroid agents for GVHD, report No.

If the recipient did not receive non-steroidal immunosuppressive agents to treat or prevent acute and / or chronic GVHD during the reporting period, report Not applicable.

Indicate Not applicable in any of the following scenarios:

  • The recipient has never received non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD.
  • This form is being completed for a subsequent HCT and the recipient has never received non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD since the start of the preparative regimen for the most recent infusion (or since the date of the most recent infusion if no preparative regimen was given).
  • The recipient stopped taking non-steroidal immunosuppressive agents (including PUVA) to treat or prevent GVHD in a previous reporting period and did not restart non-steroidal immunosuppressive agents (including PUVA) during the current reporting period.

Indicate Unknown if there is no information to determine if the recipient is still taking non-steroidal immunosuppressive agents. This option should be used sparingly and only when no judgment can be made about the recipient still receiving treatment for GVHD in the reporting period.

If the recipient has died prior to discontinuation of non-steroidal immunosuppressive agents used to treat or prevent acute and/or chronic GVHD, select Yes.

Question 209 – 210: Date final treatment administered

Indicate whether the final administration date of non-steroidal immunosuppressive agents (including PUVA) is Known or Unknown. If the final treatment date is Known, report the date when the final treatment or prophylaxis dose of non-steroidal immunosuppressive agents was administered.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
. . . . .
Last modified: Sep 23, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.